22WCGIC P-317 Calderon Plaja 7 6 5 4 3 2 1 Cancer Survival • • Focusing poor (CHT 81 were Median Functional Pathology Gastroenterology Radiodiagnostic Statistics Surgery Radiation Medical different multidisciplinary differences enhance diagnosed Management world elderly 24 reported underwent In % pathological 59 characteristics chemo % 58 our A ) Depatment 1 pt Figure1. Oncology % performance pt squamous , Ferrando A Department % - Oncology Department and class N LAEC achieved were pt received were age 12 on specialists - treatment in , Department . radiotherapy Department 12 Lopez Department in Multidisciplinary , Department care, the nCRT in Germans Andrea Plaja Salarich Clinical Esophageal Cancer pt was , % , Cataln cohort, eligible pt ≥ Germans mOS a of (LAEC) that response 1 75 literature were A , carcinomas non with definitive outcomes , Bugés 13 65 and are a Institute Germans followed management , Trias , LAEC status , Germans Catalan years, , . Jose in pathological underwent Catalan Trias - results years U i Pujol shown clinical for seems significant 3 deemed nCRT C of i Pujol - 1 M Trias Institute year nit , Hierro, C ( Trias Oncology is Institute ( ≥ . nCRT University 14 radical which pCR , i Pujol (range 2 chemo University by Layos challenging i Pujol and and and . in warranted BACKGROUND management trial of treated mOS ) of ( ), . (ICO) surgery University Oncology table candidates Hospital ( University UFEG Oncology 1 curative dCRT 32 , Caro M prompted CONCLUSION in L quality treatment, comorbidities downstaging, followed 1 Hospital ( - scenario - 30 , Manzano JL Badalona, Badalona, Badalona radiotherapy % was a 1 (ICO) Hospital ( adenocarcinomas HUGTiP – . (ICO) among Hospital ( highly had HUGTiP 2 90 to - , similar Badalona, Badalona, since of treatments - Viciano Badalona, Badalona, Barcelona, ), ), Badalona ) further HUGTiP only in at • • by us life lower HUGTiP ), Badalona, Barcelona, with whilst 1 , Font A specialized within our a dCRT was The regional relapses ( The , Barcelona, to . Barcelona . 52 its surgery including ), Badalona, ), Badalona, Barcelona, M UFEG in We for A ( ), Badalona, ), Badalona, Barcelona, , Barcelona, dCRT implement % 3 24 LAEC recurrences, , España , España S improve multimodal recurrence 29 aggressive 3 dCRT ) 7 1 group best % - : aimed % , year % compared Spain patients Spain ensures ) Spain pt ones . received and in were cohort, in Spain and supportive 24 ≥ UFEG . the Spain median 1 , García O Figure the 94 to 75 42 a % ( 79 a Spain more % rate nCRT nCRT % assess behavior, Spain approach that (n= outcomes geriatric years achieving % according multidisciplinary integrated palliative to pt of 1 vs 7 was overall 4 ) received , LAEC group . RESULTS groups nCRT frequent Barluenga the care, 21 pt and outcome higher ( % assessment with pt could often cases ) of pt similar 83 . and to chemotherapy survival ( mostly . 32 these by 14 13 12 11 10 9 8 % receive neoadjuvant However Palliative Anestesiology ) A Auxiliary Advanced Social Endocrinology E a a % in dministrative 5 than . 27 , men ) complete Colan with the . Baseline Worker pCR % pt due Distant Care of ( . retrospectively demographic, in UFEG were From P in mOS local . ractice dCRT Oncology Department, Catalan Institute of Oncology (ICO) among optimized 68 JA , Department Department Department to the Department of Oncology Department, Catalan Institute of Oncology (ICO) to 6 pt order % , Nursing Lopez - ) those referred 2012 specialists that Locally all , , , presented Germans , Catalan TNM Inferior esophageal R Catalan Oncology Recurrence Surgical in Surgical complications Surgery CHT regime Squamous carcinoma > 75years Median age (years) Germans to 7 Poster to , T4N+M0 T3N+M0 T2N+M0 Loco Distance relapse Complete pathological response Pathological downstaging Carboplatin Cisplatin Sendra establish Institute Gastro 2018 at: Institute to treatment 3. 2. 1. from Trias Department Trias at - regional Table 1.Baseline esophageal Van Oncol with chemoradiotherapy Al Oncol treatment Herskovic our i Pujol c M - i Pujol - this , haracteristics Sarraf of hospital mortality of - available 8 5FU , 150 Oncology Hagen Oncology Alvaro ( . Advanced University UFEG, esophageal 1997 - ( University , taxol 2012 first Catalan METHODS a newly results M, A, ) and or - (ICO) . P, (ICO) ) multimodal M . consultation Esophageal Institute Hospital ( junctional et Hospital ( 9 of et electronic , - et - Badalona Badalona REFERENCES Joaquin for al survival al diagnosed whom cancer . . al versus of HUGTiP locally Preoperative - HUGTiP Esophageal . Badalona Oncology , , Barcelona, Barcelona, cancer Progress C : - 10 ), Badalona, ), Badalona, Barcelona, Badalona ), Badalona, ), Badalona, Barcelona, radiotherapy 90 medical , Riquelme M , an advanced therapeutic , data (ICO) evaluated Barcelona, . Esophageal were N Spain N=42 (%) esophageal intergroup Spain - , 17 (40) 20 (48) 22 (52) 16 (73) 22 (52) 22 (52) 20 (48) 30 (71) 13 (31) Badalona, Badalona, Barcelona Barcelona, Engl 5 (12) 6 (27) dCRT carcinoma chemoradiotherapy report 70 were - - - Spain records disease J LAEC Med alone 11 Spain every cancer , Spain Hernandez of study Spain extracted plan ( : . 2012 advances N=31 (%) review . cancers Several in 21 (68) 23 (74) 10 (32) 17 (59) 29 (94) 24 (77) 18 (58) 8 (26) 1 (10) 9 (90) 9 (31) 7 (24) 5 (16) nCRT combined , 2 (6) 2 (7) 1 (3) Spain . 61 case, . patients ) . J . All Ann Clin A for in 12 ,